Abstract 2160: Tumor suppressor p53 down-regulates programmed cell death protein 4 (PDCD4) expression

2021 ◽  
Author(s):  
Wei-Hsiung Yang ◽  
Andrew P. George ◽  
William H. Yang ◽  
Chiung-Min Wang ◽  
Richard H. Yang
Keyword(s):  
Cell Death ◽  
Tumor Suppressor ◽  
Programmed Cell Death ◽  
Tumor Suppressor P53 ◽  
Pdcd4 Expression ◽  
Cell Death Protein

Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21Waf1/Cip1

2004 ◽  
Vol 287 (6) ◽  
pp. C1541-C1546 ◽  
Author(s):  
R. Göke ◽  
P. Barth ◽  
A. Schmidt ◽  
B. Samans ◽  
B. Lankat-Buttgereit
Keyword(s):  
Colon Cancer ◽  
Cell Death ◽  
Tumor Suppressor ◽  
Programmed Cell Death ◽  
Tumor Cell ◽  
Tumor Progression ◽  
Tumor Cell Lines ◽  
Cyclin Dependent Kinase ◽  
Novel Target ◽  
Cell Death Protein

We show that the recently discovered tumor suppressor pdcd4 represses the transcription of the mitosis-promoting factor cyclin-dependent kinase (CDK)1/cdc2 via upregulation of p21Waf1/Cip1. p21Waf1/Cip1 inhibits CDK4/6 and CDK2. Decrease of CDK4/6 and CDK2 enhances the binding of pRb to E2F/DP, which in turn together bind to and repress the cdc2 promoter. Upregulation of CDK1/cdc2 accompanied by a malignant change was previously reported in colon cancer. We show that expression of pdcd4 as an indirect suppressor of CDK1/cdc2 is lost in progressed carcinomas of lung, breast, colon, and prostate. Furthermore, it seems that localization and expression of pdcd4 directly correlate with tumor progression. Finally, the CDK1/cdc2 inhibitor roscovitine reduces the proliferation of several tumor cell lines, suggesting that inhibition of CDK1/cdc2 may be a useful strategy against malignant transformation. Therefore, pdcd4 might serve as a novel target for antineoplastic therapies.

Programmed Cell Death Protein 4 (PDCD4) Acts As a Tumor Suppressor in Neuroendocrine Tumor Cells

2004 ◽  
Vol 1014 (1) ◽  
pp. 220-221 ◽  
Author(s):  
RÜDIGER GÖKE ◽  
CORNELIA GREGEL ◽  
ALEXANDRA GÖKE ◽  
RUDOLF ARNOLD ◽  
HARALD SCHMIDT ◽  
...  
Keyword(s):  
Cell Death ◽  
Tumor Suppressor ◽  
Programmed Cell Death ◽  
Neuroendocrine Tumor ◽  
Tumor Cells ◽  
Cell Death Protein

scholarly journals Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future

2017 ◽  
Vol 2017 ◽  
pp. 1-10 ◽  
Author(s):  
Ece Esin
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Checkpoint Inhibitors ◽  
Innate Immune ◽  
Small Subset ◽  
New Class ◽  
Combination Strategies ◽  
Combination Methods ◽  
Immune Editing ◽  
Cell Death Protein

In the last decade, we have gained a deeper understanding of innate immune system. The mechanism of the continuous guarding of progressive mutations happening in a single cell was discovered and the production and the recognition of tumor associated antigens by the T-cells and elimination of numerous tumors by immune-editing were further understood. The new discoveries on immune mechanisms and its relation with carcinogenesis have led to development of a new class of drugs called immunotherapeutics. T lymphocyte-associated antigen 4, programmed cell death protein 1, and programmed cell death protein ligand 1 are the classes drugs based on immunologic manipulation and are collectively known as the “checkpoint inhibitors.” Checkpoint inhibitors have shown remarkable antitumor efficacy in a broad spectrum of malignancies; however, the strongest and most durable immune responses do not last long and the more durable responses only occur in a small subset of patients. One of the solutions which have been put forth to overcome these challenges is combination strategies. Among the dual use of methods, a backbone with either PD-1 or PD-L1 antagonist drugs alongside with certain cytotoxic chemotherapies, radiation, targeted drugs, and novel checkpoint stimulators is the most promising approach and will be on stage in forthcoming years.

Discovery of modulator for PD-1/PD-L1 interaction by molecular simulation and bioassay

2021 ◽  
Author(s):  
guangping Li ◽  
Haiqiong Guo ◽  
linan zhao ◽  
Huixian Feng ◽  
Huawei He ◽  
...  
Keyword(s):  
Cell Death ◽  
Programmed Cell Death ◽  
Molecular Simulation ◽  
Immune Escape ◽  
Cell Death Protein

The combination of the human programmed cell death protein 1 (hPD-1) and its ligand hPD-L1 activates the immune escape of tumors, and the blockage in PD-1/PD-L1 involved pathway can enhance...

Sign in / Sign up

Export Citation Format

Share Document